Here's What Key Metrics Tell Us About McKesson (MCK) Q4 Earnings

For the quarter ended March 2025, McKesson (MCK) reported revenue of $90.82 billion, up 19% over the same period last year. EPS came in at $10.12, compared to $6.18 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $93.7 billion, representing a surprise of -3.08%. The company delivered an EPS surprise of +3.16%, with the consensus EPS estimate being $9.81.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how McKesson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- U.S. Pharmaceutical: $83.17 billion compared to the $85.79 billion average estimate based on four analysts. The reported number represents a change of +20.9% year over year.
• Revenue- Prescription Technology Solutions: $1.34 billion compared to the $1.36 billion average estimate based on four analysts. The reported number represents a change of +13.5% year over year.
• Revenue- International: $3.46 billion versus the four-analyst average estimate of $3.55 billion. The reported number represents a year-over-year change of -2.5%.
• Revenue- Medical-Surgical Solutions: $2.85 billion compared to the $2.79 billion average estimate based on four analysts. The reported number represents a change of +0.6% year over year.
• Adjusted Operating Profit- U.S. Pharmaceutical: $1.05 billion versus the four-analyst average estimate of $1.05 billion.
• Adjusted Operating Profit- International: $102 million versus the four-analyst average estimate of $96.42 million.
• Adjusted Operating Profit- Corporate: -$165 million versus -$160.18 million estimated by four analysts on average.
• Adjusted Operating Profit- Prescription Technology Solutions: $285 million versus the four-analyst average estimate of $267.80 million.
• Adjusted Operating Profit- Medical-Surgical Solutions: $285 million compared to the $283.33 million average estimate based on four analysts.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research